About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
ASH 2019 Myeloma Highlights: Genetic Engineering of T-cells, Dara-VMP for Transplant-ineligible Pts, D-RVd as a Potential SOC for Transplant-eligible Pts & Prognostic Value of PET-CT
By
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
FEATURING
Ashley Rosko
By
UNMC 2020 Lymphoma Study Group & Hematology Highlights: A Post ASH Review
FEATURING
Ashley Rosko
12 views
March 9, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
17:46
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …
Feat.
A. Jakubowiak
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
19:24
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…
Feat.
P. Richardson
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
06:19
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Dara-KRd in NDMM Without ASCT - Final Analy…
Feat.
B. Derman
49:01
Scripps MD Anderson Cancer Center
Current Summary of the Multiple Myeloma Treatment Landscape
Feat.
R. Lu
12:35
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…
Feat.
C. Cerchione
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
16:28
Total Health
Multiple Myeloma: A New Risk-Adapted Approach
Feat.
J. Chandler
08:36
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Standard- and High-Risk ND Transplant-Eligi…
Feat.
N. Joseph
11:38
Heinz Ludwig
Maintenance Therapy in Myeloma: Which Agent and for How Long?
31:51
Indy Hematology Review
Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…
Feat.
K. Anderson
03:17
Insights from 2023 IMS Annual Meeting
IMS 2023 Insights: "Highlights From the International Myeloma S…
Feat.
J. Richter
05:47
Meletios Dimopoulos
PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…
21:51
Moffitt Cancer Center
State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? Whe…
Feat.
A. Grajales-Cruz
06:23
Integrity Continuing Education
ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VR…
Feat.
O. Landgren
13:18
Insights from 2023 IMS Annual Meeting
Highlights and Key Takeaways From the 2023 International Myeloma Soc…
Feat.
A. Jakubowiak
04:15
Indy Hematology Review
Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…
Feat.
M. Gertz
35:37
University of Colorado Division of Hematology
2024 Updates on Multiple Myeloma Treatment
Feat.
D. Sherbenou
